Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011036265 - N-ACETYL-L-CYSTEINE FOR THE TREATMENT OF ENDOMETRIOSIS

Publication Number WO/2011/036265
Publication Date 31.03.2011
International Application No. PCT/EP2010/064175
International Filing Date 24.09.2010
IPC
A61K 31/198 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A61P 15/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders; Contraceptives
CPC
A61K 31/198
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA],
A61K 33/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
A61K 9/0056
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0053Mouth and digestive tract, i.e. intraoral and peroral administration
0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
A61P 15/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
Applicants
  • IASOMAI AB [SE]/[SE] (AllExceptUS)
  • PARASASSI, Tiziana [IT]/[IT] (UsOnly)
  • PORPORA, Maria Grazia [IT]/[IT] (UsOnly)
Inventors
  • PARASASSI, Tiziana
  • PORPORA, Maria Grazia
Agents
  • IPQ IP SPECIALISTS AB
Priority Data
09171394.125.09.2009EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) N-ACETYL-L-CYSTEINE FOR THE TREATMENT OF ENDOMETRIOSIS
(FR) N-ACÉTYL-L-CYSTÉINE POUR LE TRAITEMENT DE L'ENDOMÉTRIOSE
Abstract
(EN)
The invention relates to a new prescription of NAC in the treatment of endometriosisand of indications associated withendometriosis, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in the treatment of endometriosis is proposed. In one embodiment of the present invention the prescribed treatment regimen may be used e.g. in order to control the frequency and the intensity of pain symptoms (dysmenorrhea, dyspareunia and acyclic chronic pelvic pain),to reduce the size of endometriotic lesions eventually up to their disappearance,to reduce recurrences after surgery and/ or to improve fertility. Side effects of this treatment are virtually absent and, in particular, this treatment does not hinder pregnancy.
(FR)
Cette invention concerne une nouvelle prescription de la NAC dans le traitement de l'endométriose et autres indications liées à l'endométriose chez un patient humain ou animal du type mammifère. De plus, un schéma posologique efficace de la NAC est proposé. Dans un mode de réalisation de la présente invention, le schéma posologique prescrit peut être utilisé, par exemple, pour maîtriser la fréquence et l'intensité des symptômes de douleur (dysménorrhées, dyspareunie et douleur pelvienne chronique acyclique), pour réduire la taille des lésions endométriosiques éventuellement jusqu'à leur disparition, pour réduire les récidives post-chirurgicales et/ou pour améliorer la fertilité. Les effets secondaires de ce traitement sont pratiquement inexistants et, en particulier, ce traitement n'empêche pas la grossesse/gestation.
Latest bibliographic data on file with the International Bureau